HomeBusinessHealthcareAnavex Life Sciences (AVXL) Surges On Alzheimer's Clinical Trials
Anavex Life Sciences (AVXL) Surges On Alzheimer's Clinical Trials

Anavex Life Sciences (AVXL) announced a presentation of phase 2B/3 Anavex 2-73-AD-004 at clinical trials on Alzheimer's Disease Congress 2022 and findings will be published in a peer reviewed journal. Anavex Life Sciences (AVXL) is a clinical-stage biopharmaceutical company that develops therapeutics for neurodegenerative and neurodevelopmental disorders. Their lead compound Anavex2-73 is being developed to treat Alzheimer's, Parkinson's, and other central nervous system diseases. George Tsilis weighs in on how AVXL compares to BIIB, ESALY, and LLY.

Market On Close

17 Oct 2022

ON AIR
education
7:00 pm
Your First Trade
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
ON AIR
education
7:00 pm
Your First Trade
REPLAY
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
11:00 pm
Trading 360
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US